Robert Gilbert, MD
Neurology · Atlanta, GANPI 1881685816
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $320,569 of the $412,011 with a category attached, or 77.8%. It is spread thinly across 51 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2019 at $200,128 and has fallen 98.9% since, to $2,125 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 910 payments — averaging $452.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$79K
- Amgen$69K
- Genentech USA, Inc.$64K
- Sanofi$58K
- Lilly USA, LLC$51K
- Novartis$25K
- plus $66K from 45 others
What the payments were for
- Consulting fees$49,84612%
- Speaking & faculty fees$320,56978%
- Grants$850%
- Travel & lodging$23,4056%
- Food & beverage$18,0314%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$412,011 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 178 | $164,738 |
| QuliptaAtogepant | 117 | $136,976 |
| IngrezzaValbenazine Tosylate | 12 | $88,459 |
| CopaxoneGlatiramer Acetate | 12 | $68,584 |
| Emgality PenGalcanezumab-Gnlm | 56 | $45,538 |
| Nurtec OdtRimegepant Sulfate | 38 | $43,976 |
| UbrelvyUbrogepant | 26 | $37,858 |
| BotoxOnabotulinumtoxina | 22 | $27,989 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $21,802 |
| RelpaxEletriptan Hydrobromide | 15 | $10,724 |
| FingolimodFingolimod Hcl | 27 | $7,822 |
| DilantinPhenytoin Sodium Extended | 15 | $4,540 |
| Memantine Hcl | 143 | $4,308 |
| Sumatriptan Succinate | 98 | $3,800 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 99 | $3,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Botox | $78,941 | $202,823165 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $208 | $88,45912 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $10,860 | $68,58412 claims |
| PfizerNurtec Odt, Relpax, Dilantin | $347 | $59,24068 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $1,55082 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
- Andrei SerbanescuAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.